The Integration of Reactive Oxygen Species Generation and Prodrug Activation for Cancer Therapy

Xiao’en Shi, Xu Zhang, Xinlu Zhang, Haizhen Guo and Sheng Wang

Abstract

The combination of chemotherapeutic drugs and reactive oxygen species (ROS) can improve cancer treatment outcome. Many ROS-generation strategies can specifically consume tumor-inherent oxygen and generate ROS, resulting in amplified ROS level and aggravated hypoxia. Therefore, the ROS generation strategy can integrate with prodrug activation strategy to realize synergetic therapy. In recent years, stimuli-responsive nanomedicines have been developed to realize the integration of ROS generation and prodrug activation. Triggered by a stimulus, nanomedicines can generate ROS at the tumor site, which can further activate the release of active drugs. In this review, we will summarize the latest progress of these nanomedicines and discuss the perspectives and challenges.

Keywords

Cancer therapy, hypoxia, nanomedicine, prodrug, reactive oxygen species.

Introduction

Chemotherapy, a cancer treatment approach based on small-molecule chemotherapeutic drugs, has been widely used in the clinic [1–3]. By systemic administration of drugs, the proliferation of tumor cells can be inhibited. However, serious side effects may also be caused by chemotherapy because chemotherapeutic drugs can cause damage to both tumor cells and normal ones [4–7]. Prodrugs, which refer to a class of bio-reversible drug derivatives, have attracted much attention [8]. Currently, approximately 10% of the marketed chemotherapeutic drugs worldwide are in the form of prodrugs [9]. Prodrugs do not show high pharmacological activity until they are activated; therefore, the development of prodrugs is an efficient strategy to improve the physicochemical, biopharmaceutical, or pharmacokinetic properties of drugs, overcoming drawbacks of parent drugs [10, 11].

In the past several decades, a variety of prodrugs that can be activated by in vivo stimuli such as pH, glutathione (GSH), and enzymes, have been developed (Table 1) [12–18], and some of which are already in clinical trial [19]. However, acidic condition and GSH are also presented in normal cells; therefore, the selectivity of commonly used pH- and GSH-responsive prodrugs is limited because these prodrugs can be partially activated by intracellular environments of normal cells. To improve the tumor selectivity of prodrug activation, various reactive oxygen species (ROS)−activated prodrugs based on ROS-sensitive bonds, such as thioëtal bond and peroxyalate ester, have been developed [20–26]. By exploiting nanotechnology, the ROS-responsive prodrugs and tumor-specific ROS-generating agents such as photosensitizers can be integrated into one nanomedicine. Through passive targeting, the nanomedicine will accumulate in tumor tissue. In response to certain stimulus, the nanomedicine will first generate ROS, which will further trigger the activation of ROS-responsive prodrugs, achieving chemo/ROS combination therapy. In addition, most of the ROS generation processes will consume inherent oxygen, resulting in exacerbation of tumor hypoxic environment [27–29]. Therefore, the integration of ROS-generating agents and hypoxia-activated prodrugs is also a promising approach to realize tumor-specific...
combination therapy (Figure 1). The hypoxia-responsive prodrugs consist based prodrug or polyprodrug; the other is the drug whose pharmacological activity can be activated in hypoxic environment, such as tirapazamine (TPZ) and 1,4-bis([2-(dimethylamino)-N-oxide]ethyl] amino)5,8-dihydroxy-anthracene-9,10-dione) [30–32].
This review summarizes recent advances in the cancer therapeutic strategy combining ROS generation and prodruk activation. The representative nanomedicines and their applications in cancer therapy will be introduced. Finally, the perspectives and challenges of this therapeutic strategy will also be discussed.

**ROS-triggered prodrug activation**

By conjugating drug molecules with other small molecules or polymers through ROS-sensitive linkers, ROS-responsive prodrugs can be obtained [33]. In the presence of high levels of ROS, these prodrugs can be activated to release active drugs. Compared with normal tissue, cancer cells show higher level of ROS; however, the endogenous ROS is still insufficient to realize effective prodrug activation. In the past decades, various ROS generation approaches have been used to further increase the ROS level inside cancer and thus improve the responsivity of ROS-responsive prodrugs.

Among the ROS generation approaches, photodynamic therapy (PDT) is the most commonly used one [34–36]. Qian et al. reported a ROS-responsive nanomedicine self-assembled from amphiphilic prodrug for combined local-regional PDT and chemotherapy [37]. To prepare the amphiphilic prodrug, a photosensitizer pyropheophorbide-a (PPa) and a chemotherapeutic drug camptothecin (CPT) were conjugated to poly(ethylene glycol) (PEG) simultaneously (Figure 2A). In blood circulation, both CPT and PPa are inactive, resulting in reduced side effects to the healthy tissues. Upon laser irradiation, singlet oxygen will be first produced via PPa-mediated photodynamic process. Furthermore, the ROS will cleave the thioether linker and thus lead to on-demand CPT release. Therefore, this nanomedicine can be used for combination of PDT and chemotherapy. Li et al. developed a ROS-activatable prodrug vesicle composed of unsaturated phospholipids, phospholipid-mimic doxorubicin (DOX) prodrug and PEG-modified PPa [38]. Under imaging-guided laser irradiation, ROS-mediated oxidation of unsaturated phospholipids and cleavage of thioether linkers will lead to increased permeability of vesicle and DOX prodrug activation, allowing ultrafast DOX release. In another study, Wang’s group developed a polyphosphoester-DOX conjugate-based polyprodrug nanoparticle (NP), in which the photosensitizer Ce6 was encapsulated [39]. This polyprodrug NP can achieve photo-triggered dissociation and prodrug activation. In a recent study, Wang et al. reported a ROS-responsive drug delivery nanosystem [26]. A thioether linker-containing poly-CPT prodrug was modified to iron oxide nanoparticles (IONPs). Then the polyprodrug-modified IONPs and aggregation-induced emission (AIE) photosensitizer were encapsulated into a nanomicelle formed by pH-responsive amphiphilic polymer. Under white light irradiation, the singlet oxygen produced by AIE photosensitizer will cause CPT release. Moreover, due to the pH/ROS dual responsiveness, the nanomedicine can achieve two-stage size changes for enhanced drug delivery and fast elimination.

The design of ROS-responsive heterotypic drug-photosensitizer dimer represents another strategy to realize ROS-triggered prodrug activation [40]. Recently, Sun and colleagues reported a nanomedicine that which is based on a ROS-responsive dimer [41]. The dimer was prepared by conjugating paclitaxel (PTX) with PPa via a ROS-cleavable single thioether linker (Figure 2B). With the help of PEG-lipid, the dimer can self-assemble into PEGylated prodrug (PSP) NPs with ultrahigh loading capacity. Once the PSP NPs arrive on the tumor sites via the passive targeting effect, the endogenous ROS will lead to partial release of PPa and PTX through cleavage of thioether bond. The disassembly of PSP NPs will address the aggregation-caused quenching (ACQ) effect of PPa. Therefore, the ROS generation efficiency in light-triggered PDT process will be significantly improved. This self-facilitated ROS generation further triggered prodrug activation, resulting in dual-synergistic multimodal cancer therapy. In a recent study, Chen’s group prepared a heterotypic dimer containing CPT and 2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH) [42]. The chemodrug and photosensitizer were linked by a cleavable thioether linker. The dimer-loaded NPs showed high drug loading content without serious drug leakage. Under endogenous ROS and the ROS generated in PDT process, the HRC prodrug can be activated to achieve synergistic tumor inhibition.

Besides PDT, ROS can also be generated by chemical methods [43, 44]. For example, β-lapachone (Lap) can generate hydrogen peroxide through the catalysis of the
nicotinamide adenine dinucleotide (phosphate) (NAD(P)H): quinone oxidoreductase 1 (NQO1) enzyme. Due to NQO1 overexpression of tumor cells, Lap-based nanomedicine exhibits an extremely high selectivity. Rao and colleagues reported a nanomedicine by co-loading Lap and a ROS-responsive prodrug (BDOX) in a nanomicelle [45]. Once the nanomedicines enter NQO1-overexpressed cancer cells, they will first release Lap for improving the intracellular hydrogen peroxide level. Then the BDOX prodrug will be activated by hydrogen peroxide to release free DOX. More importantly, the sequential drug release process allows the synergy of Lap and DOX to prevent drug efflux, resulting in reversal of multidrug resistance of cancer cells. The cytotoxicities of nanomedicines against NQO1-overexpressing cancer cells (4T1, MCF-7, and MCF-7 ADR) were higher than that against normal cells (NIH/3T3). Based on the characteristic of Lap, Chen et al. developed a pH/ROS dual-responsive iron-containing nanomedicine (Figure 3A) [46]. In this nanomedicine, Lap was encapsulated into polymeric micelles that assembled from a pH-responsive polymer, a ROS-responsive DOX-based polyprodrug. In intracellular acidic environment, Lap will be first released due to pH-triggered disassembly of the nanomedicine. Through iron-catalyzed Fenton reaction, the hydrogen peroxide produced by Lap will be transformed to hydroxyl radicals, which further cleave the thioketal linker between DOX and polyprodrug to release active DOX. Therefore, chemo/chemodynamic combination therapy was achieved by the cascade of hydroxyl radical generation and DOX release. Glucose oxidase (GOD), an enzyme that can convert oxygen and glucose into hydrogen peroxide, is also widely used to develop nanomedicine (Figure 3B) [47, 48]. Ge’s group has developed a series of GOD-based nanosystems for prodrug activation [49, 50]. For example, a GOD-encapsulated nanoreactor self-assembled from amphiphilic polyprodrug was prepared for oxidation/chemotherapy (Figure 3B) [49]. In acidic tumor environment, due to the permeability change of the nanoreactor membranes, glucose can diffuse into the nanoreactor and generate hydrogen peroxide under the catalysis of GOD. The high level of hydrogen peroxide will further trigger the cleavage of oxalate bonds and activate the polyprodrug, releasing active CPT. Therefore, this nanoreactor combines oxidation therapy and chemotherapy to inhibit tumor growth.

### Hypoxia-triggered prodrug activation

In most solid tumors, hypoxia is a typical characteristic [51, 52]. Some ROS generation strategies, such as type II PDT and GOD-mediated catalytic process, need to further consume tumor oxygen to produce singlet oxygen or hydrogen peroxide [53]. The exacerbated hypoxia of tumor environment can also be used as a stimulus to activate hypoxia-responsive nanomedicines. Therefore, the combination of ROS-generating agents and hypoxia-activatable prodrugs is a promising approach to achieve enhanced cancer therapy.

One type of hypoxia-activatable prodrug is one that contains hypoxia-sensitive linkers. Xie et al. developed a hypoxia-activated self-immolative PTX dimer (PTX₂-Azo) by conjugating two PTX molecules through an azobenzene (Azo) linker (Figure 4A) [54]. The PTX₂-Azo was encapsulated in the NP self-assembled from chlorin e6 (Ce6)-containing amphiphilic copolymer, obtaining Ce6/PTX₂-Azo NP. Attributing to the passive targeting effect, the Ce6/PTX₂-Azo NP with a size of approximately 100 nm can effectively accumulate in tumor tissue. Upon laser irradiation, the encapsulated photosensitizer Ce6 will consume inherent oxygen and generate singlet oxygen to induce cell apoptosis. Due to the PDT-aggravated hypoxia, the Azo linker of PTX₂-Azo prodrug will be cleaved by reductases. Then the active PTX will be released through a cascade elimination reaction. Through the combination of PDT and prodrug activation, excellent antitumor efficacy can be achieved.

In another study, Pu’s group reported a nanoprodug (denoted as SPNpd) for PDT and hypoxia-activated drug release [55]. The SPNpd was self-assembled from a drug-conjugated amphiphilic semiconducting polymer. Bromoisophosphoramide mustard intermediate (IPM-Br), a chemotherapeutic drug, was conjugated to the SPNpd by using a hypoxia-cleavable linker (Figure 4B). In this system, the light-responsive semiconducting polymer was used as a photosensitizer, which can produce ROS under 808-nm light irradiation. Meanwhile, with the consumption of oxygen, the hypoxia of tumor exacerbated. In such a hypoxic condition, the linker between IPM-Br and the polymer will be cleaved by nitroreductase-catalyzed reduction, resulting in hypoxia-activated IPM-Br release. The activity will further induce DNA crosslinking and subsequent cellular apoptosis.

![Figure 3](image-url) (A) Chemical structure of PEG-PtkDOX. (B) Chemical structure of ROS-responsive polyprodrug.
Therefore, the SPNpd can realize synergistic photodynamic/chemotherapy and effective inhibition of tumor growth.

Another type of hypoxia-activatable prodrug mainly contains quinone-based prodrugs and N-oxide prodrugs that show little toxicity in normoxic condition and high toxicity in hypoxic condition. Among the prodrugs, TPZ is a widely studied one. In hypoxic condition, TPZ can be converted into toxic radicals through bioreduction (Figure 5) [56]. Therefore, the development of hybrid nanosystems that combine TPZ and photosensitizer represents a promising way to realize combination therapy. Porphyrinic metal-organic framework (MOF), which self-assembled from metal ion and porphyrin photosensitizer through coordination interactions, has attracted much attention. Porphyrinic MOF can be used not only as a nanophotosensitizer for PDT, but also as a nanocarrier for delivering other therapeutic agents. Li et al. reported a TPZ-loaded core–shell upconversion nanoparticle in porphyrinic MOFs (TPZ/UCSs) for combination therapy [57]. Under near-infrared (NIR) light irradiation, the upconversion nanoparticle core will convert the NIR light to visible light to activate photosensitizer in MOF shell, generating 1O2 efficiently. Furthermore, PDT-aggravated tumor hypoxia will activate the pharmacological activity of encapsulated TPZ, enabling combinational photodynamic/chemotherapy. This study provides a promising nanoplatform in fighting tumor through the integration of NIR-triggered ROS generation and hypoxia-triggered produrg activation.

The hypoxia-responsive prodrugs have also been combined with GOD to develop nanomedicine [58, 59]. Wu et al. constructed a hybrid nanoreactor (denoted as HGTFT) composed of human serum albumin (HSA), GOD, TPZ, Fe3+ and tannic acid (TA) for cascade chemo-chemodynamic therapy [60]. In cancer cells, GOD will first consume glucose and oxygen for starvation therapy, resulting in the production of hydrogen peroxide and aggravated hypoxia. Through TA-accelerated Fenton reaction, the hydrogen peroxide will react with iron ions to produce highly toxic hydroxyl radicals for chemodynamic therapy. Meanwhile, the hypoxic environment will activate TPZ to generate BTZ• for chemotherapy. The in vitro and in vivo results demonstrated excellent biosafety and enhanced anticancer activity of the HGTFT nanoreactor. Therefore, this nanoreactor has great potential for clinical applications.

Cascade of prodrug release and activation

As we discussed above, the PDT process will lead to two consequences, high ROS level and aggravated hypoxia, both of which can be used for drug release and prodrug activation. In order to make full use of these two consequences, Sun and colleagues developed a nanomedicine that combines ROS-triggered prodrug release and hypoxia-triggered prodrug activation [61]. As shown in Figure 6, two types of heterodimeric dimers that based on hypoxia-responsive prodrug PR104A and photosensitizer PPa were synthesized. The PR104A and PPa were conjugated via a ROS-sensitive thioether or thioketal linkage. Then the heterodimeric dimers self-assembled to form prodrug-NPs with a dense intermolecular-packing structure. Under laser irradiation, the thioether or thioketal linkages between PPa and PR104A will be cleaved because electrons can be transferred from

![Figure 4](image)

(A) Chemical structure of PTX2-Azo. (B) Chemical structure of hypoxia-responsive prodrug.

![Figure 5](image)

Chemical structures of TPZ and activated TPZ.

![Figure 6](image)

Chemical structures of PR104A-S-PPa and PR104A-TK-PPa.
PPa to the sulfur atoms via photoinduced electron transfer. Therefore, the PR104A prodrug will be released, causing disassembly of prodrug-NPs. As the ACQ effect was relieved, the PPa will efficiently consume oxygen and produce singlet oxygen to further promote the PR104A release. Meanwhile, the hypoxic condition caused by oxygen consumption will facilitate the activation of hypoxia-sensitive PR104A to realize DNA damage.

### Conclusion and outlook

Compared with normal tissue, tumor tissue has unique structural and metabolic characteristics, such as weak acidic microenvironment, hypoxia condition, high ROS level, and overexpression of specific enzymes. Based on these special characteristics, prodrugs that can be activated in tumor site exhibit great potential in antitumor therapy. With the developments of stimuli-sensitive moieties, various prodrug and polyprodrug systems have been designed and applied in cancer treatments. However, the selectivity of generally used pH- and GSH-activated prodrugs is still limited. Many ROS generation strategies, such as PDT, can specifically consume tumor inherent oxygen and generate ROS, resulting in amplified ROS level and aggravated hypoxia. In recent years, nanomedicines that integrate ROS generation strategies with ROS- or hypoxia-responsive prodrugs have been developed. Upon accumulation in tumor tissue, the nanomedicines will first generate ROS in tumor site, which can not only cause cell death directly, but also activate prodrugs to improve therapeutic efficiency. Therefore, these nanomedicines show great potential to realize combination therapy with improved selectivity.

In this review, we summarized recent advances of the integration strategy. Although significant progress has been made in the design and application of ROS-responsive and hypoxia-responsive prodrugs, there are still some obstacles and challenges. For example, the efficiency of the first stage (ROS generation) will significantly affect the effectiveness of second stage (prodrug activation). Particularly, this strategy is difficult to apply to the treatment of hypoxic tumors. Furthermore, in some systems, the prodrug activation process needs to consume ROS, resulting in unsatisfactory combination treatment outcome. Therefore, for the future research, more efforts should be put toward to address these issues. In addition, ROS generation can also be triggered by engineered bacteria, which provided an opportunity for interdisciplinary integration.

### Conflict of interest

The authors declare no conflict of interest.

### Acknowledgements

This work was supported by the National Natural Science Foundation of China (32000991), the Young Elite Scientists Sponsorship Program by Tianjin (TJSQNTJ-2020-02), and Tianjin Research Innovation Project for Postgraduate Students (2020YJSB130).

### References

[1] Yoo J-W, Irvine DJ, Discher DE, Mitragotri S. Bio-inspired, bio-engineered and biomimetic drug delivery carriers. Nat Rev Drug Discovery 2011;10:521-35. [PMID: 21720407 DOI: 10.1038/nrd3499]

[2] Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumours. Nat Rev Clin Oncol 2010;7:653-64. [PMID: 20838415 DOI: 10.1038/nrclinonc.2010.139]

[3] Zhang X, Wang S, Cheng G, Yu P, Chang J, et al. Cascade drug-release strategy for enhanced anticancer therapy. Matter 2021;4:26-53. [PMID: 33718863 DOI: 10.1016/j.matt.2020.10.002]

[4] Cheng Z, Al Zaki A, Hui JZ, Muszykantov VR, Tsourkas A. Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities. Science 2012;338:903-10. [PMID: 23161990 DOI: 10.1126/science.1226338]

[5] Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, et al. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol 2007;2:751-60. [PMID: 18654426 DOI: 10.1038/nnano.2007.387]

[6] Thakor AS, Gambhir SS. Nanonoology: the future of cancer diagnosis and therapy. Ca-Cancer J Clin 2013;63:395-418. [PMID: 24114523 DOI: 10.3322/caac.21199]

[7] Wang S, Huang P, Chen X. Hierarchical targeting strategy for enhanced tumor tissue accumulation/retention and cellular internalization. Adv Mater 2016;28:7340-64. [PMID: 27255214 DOI: 10.1002/adma.201601498]

[8] Rautio J, Kumpulainen H, Heinimach T, Oliyai R, Oh D, et al. Prodrugs: design and clinical applications. Nat Rev Drug Discovery 2008;7:255-70. [PMID: 18219308 DOI: 10.1038/nrd2468]

[9] Rautio J, Meanwell NA, Di L, Hageman M. J. The expanding role of prodrugs in contemporary drug design and development. Nat Rev Drug Discovery 2018;17:559-87. [PMID: 29700501 DOI: 10.1038/nrd.2018.46]

[10] Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv Drug Delivery Rev 2007;59:677-94. [PMID: 17628203 DOI: 10.1016/j.addr.2007.05.013]

[11] Pradere U, Garnier-Amblard EC, Coats SJ, Amblard F, Schinazi RF. Synthesis of nucleoside phosphate and phosphonate prodrugs. Chem Rev 2014;114:9154-218. [PMID: 25144792 DOI: 10.1021/cr5002035]

[12] Wang S, Yu G, Wang Z, Jacobson O, Tian R, et al. Hierarchical tumor microenvironment-responsive nanomedicine for programmed delivery of chemotherapeutics. Adv Mater 2018;30:1803926. [PMID: 30168612 DOI: 10.1002/adma.201803926]

[13] Zhang F, Zhu G, Jacobson O, Liu Y, Chen K, et al. Transformative nanomedicine of an amphiphilic camptothecin prodrug for long circulation and high tumor uptake in cancer therapy. ACS Nano 2017;11:8838-48. [PMID: 28858467 DOI: 10.1021/acsnano.7b03003]

[14] Zhang F, Ni Q, Jacobson O, Cheng S, Liao A, et al. Polymeric nanoparticles with a glutathione-sensitive heterodimeric multifunctional
Mini Review

prodrug for in vivo drug monitoring and synergistic cancer therapy. Angew Chem Int Ed 2018;57:7066-70. [PMID: 29624828 DOI: 10.1002/anie.201801984]

[15] Yu G, Zhang M, Saha ML, Mao Z, Chen J, et al. Antitumor activity of a unique polymer that incorporates a fluorescent self-assembled metalacrylate. J Am Chem Soc 2017;139:15940-9. [PMID: 29019660 DOI: 10.1021/jacs.7b09724]

[16] Hu X, Zhao S, Liu G, Xing D, Liang H, et al. Concurrent drug unloading and permeabilization of polyprodrug-gated crosslinked vesicles for cancer combination chemotherapy. Adv Mater 2018;30:1706307. [PMID: 29635863 DOI: 10.1002/adma.201706307]

[17] Guo X, Wang L, Duval K, Fan J, Zhou S, et al. Dimeric drug-polymer micelles with acid-active tumor targeting and FRET-traceable drug release. Adv Mater 2018;30:1705436. [PMID: 29210480 DOI: 10.1002/adma.201705436]

[18] Wang S, Zhang F, Yu G, Wang Z, Jacobson O, et al. Zwitterion-to-cationic charge conversion polyprodrug nanomedicine for enhanced drug delivery. Theranostics 2020;10:6629-37. [PMID: 32550894 DOI: 10.7150/thno.47849]

[19] Xie A, Hanif S, Ouyang J, Tang ZM, Kong N, et al. Stimuli-responsive polydrug-based cancer nanomedicine. EBioMedicine 2020;56:102821. [PMID: 32505922 DOI: 10.1016/j.ebiom.2020.102821]

[20] Yuan Y, Liu J, Liu B. Conjugated-polyelectrolyte-based polyprodrug: targeted and image-guided photodynamic and chemotherapy with on-demand drug release upon irradiation with a single light source. Angew Chem Int Ed 2014;53:7163-8. [PMID: 24861823 DOI: 10.1002/anie.201402189]

[21] Wang S, Wang Z, Yu G, Zhou Z, Jacobson O, et al. Tumor-specific drug release and reactive oxygen species generation for cancer chemotherapeutic synergistic combination therapy. Adv Sci 2019;6:1801986. [PMID: 30886808 DOI: 10.1002/advs.201801986]

[22] Li J, Ke W, Wang L, Huang M, Yin W, et al. Self-sufficing H2O2-responsive nanocarriers through tumor-specific H2O2 production for synergistic oxidation-chemistry. J Control Release 2016;225:64-74. [PMID: 26806789 DOI: 10.1016/j.jconrel.2016.01.029]

[23] Pei Q, Hu X, Zheng X, Liu S, Li Y, et al. Light-activatable red blood cell membrane-camouflaged dimeric prodrug nanoparticles for synergistic photodynamic/chemotherapy. ACS Nano 2018;12:1630-41. [PMID: 29346736 DOI: 10.1021/acsnano.7b08219]

[24] Yue C, Yang Y, Zhang C, Alfranca G, Cheng S, et al. Ros-responsive mitochondria-targeting blended nanoparticles: chemo- and photodynamic synergistic therapy for lung cancer with on-demand drug release upon irradiation with a single light source. Theranostics 2016;6:2352-66. [PMID: 27877240 DOI: 10.7150/thno.15433]

[25] Zhang W, Hu X, Shen Q, Xing D. Mitochondria-specific drug release and reactive oxygen species burst induced by polyprodrug nanoreactors can enhance chemotherapy. Nat Commun 2019;10:1704. [PMID: 30979985 DOI: 10.1038/s41467-019-09566-3]

[26] Cheng G, Zong W, Guo H, Li F, Zhang X, et al. Programmed size-changeable nanotheranostic agents for enhanced imaging guided chemotherapy/photodynamic combination therapy and fast elimination. Adv Mater 2021;33:2100398. [PMID: 33876500 DOI: 10.1002/adma.202100398]

[27] Liu IN, Bu WB, Shi JL. Chemical design and synthesis of functionalized probes for imaging and treating tumor hypoxia. Chem Rev 2017;117:6160-224. [PMID: 28426202 DOI: 10.1021/acs.chemrev.6b00525]

[28] Wang S, Tian R, Zhang X, Cheng G, Yu P, et al. Beyond photo: Xdytox-enabled cascade drug reactions for efficient drug delivery and enhanced combination therapy. Adv Sci 2021;8:2002927. [PMID: 34026433 DOI: 10.1002/advs.202002927]

[29] Lin QN, Bao CY, Yang YL, Liang QN, Zhang DS, et al. Highly discriminating photorelease of anticancer drugs based on hypoxia activatable phototrigger conjugated chitosan nanoparticles. Adv Mater 2013;25:1981-6. [PMID: 23401259 DOI: 10.1002/adma.201204455]

[30] Sharma A, Arambula JF, Koo S, Kumar R, Singh H, et al. Hypoxia-targeted drug delivery. Chem Soc Rev 2019;48:771-813. [PMID: 30575832 DOI: 10.1039/c8cs00304a]

[31] He ZM, Dai YL, Li XL, Guo D, Liu YJ, et al. Hybrid nanomedicine fabricated from photosensitizer-terminated metal-organic framework nanoparticles for photodynamic therapy and hypoxia-activated cascade chemotherapy. Small 2019;15:1804131. [PMID: 30565431 DOI: 10.1002/smll.201904131]

[32] Xue X, Saw PE, Tao W, Li Y, Ji X, et al. Ros-responsive polyprodrug nanoparticles for triggered drug delivery and effective cancer therapy. Adv Mater 2017;29:1700141. [PMID: 28681981 DOI: 10.1002/adma.201700141]

[33] Guo X, Zou F, Feng B, Wang T, Dui C, et al. Theranostic produgs as reactive oxygen species-triggered ultrafast drug release and local-regional therapy of metastatic triple-negative breast cancer. Adv Mater 2017;29:1703674. [PMID: 31034679 DOI: 10.1002/adma.202005918]

[34] Zhuo F, Feng B, Wang T, Wang D, Cui Z, et al. Theranostic prodrug vesicles for reactive oxygen species-triggered ultrafast drug release and enhanced combination of chemotherapy and photodynamic therapy. Adv Funct Mater 2020;30:2005918. [DOI: https://doi.org/10.1002/adfm.202005918]

[35] Lin Q, Bao CY, Yang YL, Liang QN, Zhang DS, et al. Highly discriminating photorelease of anticancer drugs based on hypoxia activatable phototrigger conjugated chitosan nanoparticles. Adv Mater 2013;25:1981-6. [PMID: 23401259 DOI: 10.1002/adma.201204455]
Xu G, Guo W, Gu X, Wang Z, Wang R, et al. Hydrogen sulfide-specific and NIR-light-controllable synergistic activation of fluorescent theranostic prodrugs for imaging-guided chemo-photothermal cancer therapy. CCS Chem 2020;2:527-38. [DOI: 10.31635/ccschem.020.201900072]

Tang L, Yang Z, Zhou Z, Ma Y, Kiesewetter DO, et al. A logic-gated modular nanovesicle enables programmable drug release for on-demand chemotherapy. Theranostics 2019;9:1358-68. [PMID: 30867836 DOI: 10.7150/thno.32106]

Yang J, Zhai S, Qin H, Yan H, Xing D, et al. NIR-controlled morphology transformation and pulsatile drug delivery based on multifunctional phototheranostic nanoparticles for photoacoustic imaging-guided photothermal-chemotherapy. Biomaterials 2018;176:1-12. [PMID: 29842986 DOI: 10.1016/j.biomaterials.2018.05.033]